Working together to deliver cell and gene therapies for people impacted by serious diseases Learn More Our inspiration Learn More Pipeline Explore R&D pz-cel (prademagene zamikeracel) BLA submitted for investigational autologous, COL7A1 gene-corrected epidermal sheets for RDEB. Learn More ABO-50X Exploring the potential of ABO-50X for the treatment of genetic eye disorders. Learn More Latest News Nov 27, 2023 Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA) View Press Release Nov 13, 2023 Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments View Press Release Nov 1, 2023 Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View Press Release View All Manufacturing at The Elisa Linton Center for Rare Disease Therapies Learn More
